The influence of monoclonal antibodies for cancer treatment on the endocrine system

[1] Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 1996; 8: 765–772 AgataY. KawasakiA. NishimuraH. IshidaY. TsubataT. YagitaH. HonjoT. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int. Immunol. 1996 8 765 772 10.1093/intimm/8.5.7658671665 Search in Google Scholar

[2] Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586 ArimaH. IwamaS. InabaH. AriyasuH. MakitaN. OtsukiM. KageyamaK. ImagawaA. AkamizuT. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society Endocr. J. 2019 66 581 586 10.1507/endocrj.EJ19-016331243183 Search in Google Scholar

[3] Armand P., Chen Y.B., Redd R.A., Joyce R.M., Bsat J., Jeter E., Merryman R.W., Coleman K.C., Dahi P.B., Nieto Y., LaCasce A.S., Fisher D.C., Ng S.Y., Odejide O.O., Freedman A.S., et al.: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019; 134: 22–29 ArmandP. ChenY.B. ReddR.A. JoyceR.M. BsatJ. JeterE. MerrymanR.W. ColemanK.C. DahiP.B. NietoY. LaCasceA.S. FisherD.C. NgS.Y. OdejideO.O. FreedmanA.S. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation Blood 2019 134 22 29 10.1182/blood.2019000215660995530952672 Search in Google Scholar

[4] Bavencio – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/bavencio-epar-product-information_en.pdf (25.09.2020) Bavencio – Summary of Product Characteristics https://www.ema.europa.eu/en//documents/product-information/bavencio-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[5] Bhasin S., Brito J.P., Cunningham G.R., Hayes F.J., Hodis H.N., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Wu F.C., Yialamas M.A.: Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2018; 103: 1715–1744 BhasinS. BritoJ.P. CunninghamG.R. HayesF.J. HodisH.N. MatsumotoA.M. SnyderP.J. SwerdloffR.S. WuF.C. YialamasM.A. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2018 103 1715 1744 10.1210/jc.2018-0022929562364 Search in Google Scholar

[6] Bornstein S.R., Allolio B., Arlt W., Barthel A., Don-Wauchope A., Hammer G.D., Husebye E.S., Merke D.P., Murad M.H., Stratakis C.A., Torpy D.J.: Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2016; 101: 364–389 BornsteinS.R. AllolioB. ArltW. BarthelA. Don-WauchopeA. HammerG.D. HusebyeE.S. MerkeD.P. MuradM.H. StratakisC.A. TorpyD.J. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2016 101 364 389 10.1210/jc.2015-1710488011626760044 Search in Google Scholar

[7] Carlé A., Pedersen I.B., Knudsen N., Perrild H., Ovesen L., Andersen S., Laurberg P.: Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control study. Am. J. Med., 2016; 129: 1082–1092 CarléA. PedersenI.B. KnudsenN. PerrildH. OvesenL. AndersenS. LaurbergP. Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control study Am. J. Med. 2016 129 1082 1092 10.1016/j.amjmed.2016.06.01327393881 Search in Google Scholar

[8] Caturegli P., Di Dalmazi G., Lombardi M., Grosso F., Larman H.B., Larman T., Taverna G., Cosottini M., Lupi I.: Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am. J. Pathol., 2016; 186: 3225–3235 CaturegliP. Di DalmaziG. LombardiM. GrossoF. LarmanH.B. LarmanT. TavernaG. CosottiniM. LupiI. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series Am. J. Pathol. 2016 186 3225 3235 10.1016/j.ajpath.2016.08.020522529427750046 Search in Google Scholar

[9] Caturegli P., Newschaffer C., Olivi A., Pomper M.G., Burger P.C., Rose N.R.: Autoimmune hypophysitis. Endocr. Rev., 2005; 26: 599–614 CaturegliP. NewschafferC. OliviA. PomperM.G. BurgerP.C. RoseN.R. Autoimmune hypophysitis Endocr. Rev. 2005 26 599 614 10.1016/B978-0-12-384929-8.00045-9 Search in Google Scholar

[10] Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., Fong L.: Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med., 2014; 6: 238ra70 ChaE. KlingerM. HouY. CummingsC. RibasA. FahamM. FongL. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients Sci. Transl. Med. 2014 6 238ra70 10.1126/scitranslmed.3008211455809924871131 Search in Google Scholar

[11] Chabner B.A., Roberts T.G. Jr.: Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005; 5: 65–72 ChabnerB.A. RobertsT.G.Jr. Timeline: Chemotherapy and the war on cancer Nat. Rev. Cancer 2005 5 65 72 10.1038/nrc152915630416 Search in Google Scholar

[12] Chalan P., Di Dalmazi G., Pani F., De Remigis A., Caturegli P.: Thyroid dysfunctions secondary to cancer immunotherapy. J. Endocrinol. Invest., 2018; 41: 625–638 ChalanP. Di DalmaziG. PaniF. De RemigisA. CaturegliP. Thyroid dysfunctions secondary to cancer immunotherapy J. Endocrinol. Invest. 2018 41 625 638 10.1007/s40618-017-0778-8 Search in Google Scholar

[13] Chamberlain J.J., Rhinehart A.S., Shaefer C.F. Jr, Neuman A.: Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann. Intern. Med., 2016; 164: 542–552 ChamberlainJ.J. RhinehartA.S. ShaeferC.F.Jr NeumanA. Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association standards of medical care in diabetes Ann. Intern. Med. 2016 164 542 552 10.7326/M15-3016 Search in Google Scholar

[14] Chang L.S., Barroso-Sousa R., Tolaney S.M., Hodi F.S, Kaiser U.B., Min L.: Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev., 2019; 40: 17–65 ChangL.S. Barroso-SousaR. TolaneyS.M. HodiF.S KaiserU.B. MinL. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints Endocr. Rev. 2019 40 17 65 10.1210/er.2018-00006 Search in Google Scholar

[15] Chau C.H., Steeg P.S, Figg W.D.: Antibody-drug conjugates for cancer. Lancet, 2019; 394: 793–804 ChauC.H. SteegP.S FiggW.D. Antibody-drug conjugates for cancer Lancet 2019 394 793 804 10.1016/S0140-6736(19)31774-X Search in Google Scholar

[16] Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375 CorselloS.M. BarnabeiA. MarchettiP. De VecchisL. SalvatoriR. TorinoF. Endocrine side effects induced by immune checkpoint inhibitors J. Clin. Endocrinol. Metab. 2013 98 1361 1375 10.1210/jc.2012-407523471977 Search in Google Scholar

[17] Darvin P., Toor S.M., Nair V.S., Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11 DarvinP. ToorS.M. NairV.S. ElkordE. Immune checkpoint inhibitors: Recent progress and potential biomarkers Exp. Mol. Med. 2018 50 1 11 10.1038/s12276-018-0191-1629289030546008 Search in Google Scholar

[18] De Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156 De FiletteJ. AndreescuC.E. CoolsF. BravenboerB. VelkeniersB. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors Horm. Metab. Res. 2019 51 145 156 10.1055/a-0843-336630861560 Search in Google Scholar

[19] Dillard T., Yedinak C.G., Alumkal J., Fleseriu M.: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary, 2010; 13: 29–38 DillardT. YedinakC.G. AlumkalJ. FleseriuM. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes Pituitary 2010 13 29 38 10.1007/s11102-009-0193-z19639414 Search in Google Scholar

[20] Dyrka K., Miedziaszczyk M., Szałek E., Łącka K.: Drugs used in viral diseases – their mechanism of action, selected adverse effects and safety during pregnancy and lactation. Postępy Hig. Med. Dośw., 2019; 73: 491–507 DyrkaK. MiedziaszczykM. SzałekE. ŁąckaK. Drugs used in viral diseases – their mechanism of action, selected adverse effects and safety during pregnancy and lactation Postępy Hig. Med. Dośw. 2019 73 491 507 10.5604/01.3001.0013.5249 Search in Google Scholar

[21] Emens L.A., Cruz C., Eder J.P., Braiteh F., Chung C., Tolaney S.M., Kuter I., Nanda R., Cassier P.A., Delord J.P., Gordon M.S., ElGabry E., Chang C.W., Sarkar I., Grossman W., et al.: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol., 2019; 5: 74–82 EmensL.A. CruzC. EderJ.P. BraitehF. ChungC. TolaneyS.M. KuterI. NandaR. CassierP.A. DelordJ.P. GordonM.S. ElGabryE. ChangC.W. SarkarI. GrossmanW. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study JAMA Oncol. 2019 5 74 82 10.1001/jamaoncol.2018.4224643977330242306 Search in Google Scholar

[22] Faje A.T., Sullivan R., Lawrence D., Tritos N.A., Fadden R., Klibanski A., Nachtigall L.: Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab., 2014; 99: 4078–4085 FajeA.T. SullivanR. LawrenceD. TritosN.A. FaddenR. KlibanskiA. NachtigallL. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma J. Clin. Endocrinol. Metab. 2014 99 4078 4085 10.1210/jc.2014-230625078147 Search in Google Scholar

[23] Fassett D.R., Couldwell W.T.: Metastases to the pituitary gland. Neurosurg. Focus., 2004; 16: E8 FassettD.R. CouldwellW.T. Metastases to the pituitary gland Neurosurg. Focus. 2004 16 E8 10.3171/foc.2004.16.4.9 Search in Google Scholar

[24] Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F.: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer, 2018; 103: 356–387 FerlayJ. ColombetM. SoerjomataramI. DybaT. RandiG. BettioM. GavinA. VisserO. BrayF. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Eur. J. Cancer 2018 103 356 387 10.1016/j.ejca.2018.07.00530100160 Search in Google Scholar

[25] Ferrari S.M., Fallahi P., Galetta F., Citi E., Benvenga S., Antonelli A.: Thyroid disorders induced by checkpoint inhibitors. Rev. Endocr. Metab. Disord., 2018; 19: 325–333 FerrariS.M. FallahiP. GalettaF. CitiE. BenvengaS. AntonelliA. Thyroid disorders induced by checkpoint inhibitors Rev. Endocr. Metab. Disord. 2018 19 325 333 10.1007/s11154-018-9463-230242549 Search in Google Scholar

[26] Freeman-Keller M., Kim Y., Cronin H., Richards A., Gibney G., Weber J.S.: Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res., 2016; 22: 886–894 Freeman-KellerM. KimY. CroninH. RichardsA. GibneyG. WeberJ.S. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes Clin. Cancer Res. 2016 22 886 894 10.1158/1078-0432.CCR-15-1136475580926446948 Search in Google Scholar

[27] Gauci M.L., Laly P., Vidal-Trecan T., Baroudjian B., Gottlieb J., Madjlessi-Ezra N., Da Meda L., Madelaine-Chambrin I., Bagot M., Basset-Seguin N., Pages C., Mourah S., Boudou P., Lebbé C., Gautier J.F.: Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review. Cancer Immunol. Immunother., 2017; 66: 1399–1410 GauciM.L. LalyP. Vidal-TrecanT. BaroudjianB. GottliebJ. Madjlessi-EzraN. Da MedaL. Madelaine-ChambrinI. BagotM. Basset-SeguinN. PagesC. MourahS. BoudouP. LebbéC. GautierJ.F. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review Cancer Immunol. Immunother. 2017 66 1399 1410 10.1007/s00262-017-2033-828634815 Search in Google Scholar

[28] Gharwan H., Groninger H.: Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications. Nat. Rev. Clin. Oncol., 2016; 13: 209–227 GharwanH. GroningerH. Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications Nat. Rev. Clin. Oncol. 2016 13 209 227 10.1038/nrclinonc.2015.21326718105 Search in Google Scholar

[29] Ha D., Tanaka A., Kibayashi T., Tanemura A., Sugiyama D., Wing J.B., Lim E.L., Teng K.W., Adeegbe D., Newell E.W., Katayama I., Nishikawa H., Sakaguchi S.: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl. Acad. Sci. USA, 2019; 116: 609–618 HaD. TanakaA. KibayashiT. TanemuraA. SugiyamaD. WingJ.B. LimE.L. TengK.W. AdeegbeD. NewellE.W. KatayamaI. NishikawaH. SakaguchiS. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody Proc. Natl. Acad. Sci. USA 2019 116 609 618 10.1073/pnas.1812186116632997930587582 Search in Google Scholar

[30] Haanen J.B., Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K., ESMO Guidelines Committee: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017; 28: iv119–iv142 HaanenJ.B. CarbonnelF. RobertC. KerrK.M. PetersS. LarkinJ. JordanK. ESMO Guidelines Committee Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2017 28 iv119 iv142 10.1093/annonc/mdx22528881921 Search in Google Scholar

[31] Haanen J.B., Robert C.: Immune checkpoint inhibitors. Prog. Tumor Res., 2015; 42: 55–66 HaanenJ.B. RobertC. Immune checkpoint inhibitors Prog. Tumor Res. 2015 42 55 66 10.1159/00043717826382943 Search in Google Scholar

[32] Hafeez U., Gan H.K., Scott A.M.: Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol., 2018; 41: 114–121 HafeezU. GanH.K. ScottA.M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases Curr. Opin. Pharmacol. 2018 41 114 121 10.1016/j.coph.2018.05.010 Search in Google Scholar

[33] Hodi F.S., Chesney J., Pavlick A.C., Robert C., Grossman K.F., McDermott D.F., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff M.S., Minor D.R., Salama A.K., Taylor M.H., et al.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol., 2016; 17: 1558–1568 HodiF.S. ChesneyJ. PavlickA.C. RobertC. GrossmanK.F. McDermottD.F. LinetteG.P. MeyerN. GiguereJ.K. AgarwalaS.S. ShaheenM. ErnstoffM.S. MinorD.R. SalamaA.K. TaylorM.H. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Lancet Oncol. 2016 17 1558 1568 10.1016/S1470-2045(16)30366-7 Search in Google Scholar

[34] Horn L., Mansfield A.S., Szczęsna A., Havel L., Krzakowski M., Hochmair M.J., Huemer F., Losonczy G., Johnson M.L., Nishio M., Reck M., Mok T., Lam S., Shames D.S., Liu J., et al.: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med., 2018; 379: 2220–2229 HornL. MansfieldA.S. SzczęsnaA. HavelL. KrzakowskiM. HochmairM.J. HuemerF. LosonczyG. JohnsonM.L. NishioM. ReckM. MokT. LamS. ShamesD.S. LiuJ. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer N. Engl. J. Med. 2018 379 2220 2229 10.1056/NEJMoa180906430280641 Search in Google Scholar

[35] Iglesias P.: Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur. J. Intern. Med., 2018; 47: 6–13 IglesiasP. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach Eur. J. Intern. Med. 2018 47 6 13 10.1016/j.ejim.2017.08.01928826822 Search in Google Scholar

[36] Illouz F., Briet C., Cloix L., Le Corre Y., Baize N., Urban T., Martin L., Rodien P.: Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists. Cancer Med., 2017; 6: 1923–1929 IllouzF. BrietC. CloixL. Le CorreY. BaizeN. UrbanT. MartinL. RodienP. Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists Cancer Med. 2017 6 1923 1929 10.1002/cam4.1145554887628719055 Search in Google Scholar

[37] Imfinzi – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/imfizi-epar-product-information_en.pdf (25.09.2020) Imfinzi – Summary of Product Characteristics https://www.ema.europa.eu/en//documents/product-information/imfizi-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[38] Iwama S., De Remigis A., Callahan M.K., Slovin S.F., Wolchok J.D., Caturegli P.: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med., 2014; 6: 230ra45 IwamaS. De RemigisA. CallahanM.K. SlovinS.F. WolchokJ.D. CaturegliP. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody Sci. Transl. Med. 2014 6 230ra45 10.1126/scitranslmed.300800224695685 Search in Google Scholar

[39] Iyer P.C., Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S.N., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251 IyerP.C. CabanillasM.E. WaguespackS.G. HuM.I. ThosaniS.N. LavisV.R. BusaidyN.L. SubudhiS.K. DiabA. DaduR. Immune-related thyroiditis with immune checkpoint inhibitors Thyroid 2018 28 1243 1251 10.1089/thy.2018.0116615735930132401 Search in Google Scholar

[40] Joo W.D., Visintin I., Mor G.: Targeted cancer therapy – Are the days of systemic chemotherapy numbered? Maturitas, 2013; 76: 308–314 JooW.D. VisintinI. MorG. Targeted cancer therapy – Are the days of systemic chemotherapy numbered? Maturitas 2013 76 308 314 10.1016/j.maturitas.2013.09.008461002624128673 Search in Google Scholar

[41] Joshi M.N., Whitelaw B.C., Palomar M.T., Wu Y., Carroll P.V.: Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin. Endocrinol., 2016; 85: 331–339 JoshiM.N. WhitelawB.C. PalomarM.T. WuY. CarrollP.V. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review Clin. Endocrinol. 2016 85 331 339 10.1111/cen.1306326998595 Search in Google Scholar

[42] June C.H., Warshauer J.T., Bluestone J.A.: Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med., 2017; 23: 540–547 JuneC.H. WarshauerJ.T. BluestoneJ.A. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med. 2017 23 540 547 10.1038/nm.432128475571 Search in Google Scholar

[43] Kalogeras K.T., Nieman L.K., Friedman T.C., Doppman J.L., Cutler G.B. Jr, Chrousos G.P., Wilder R.L., Gold P.W., Yanovski J.A.: Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. J Clin Invest., 1996; 97: 2045–2050 KalogerasK.T. NiemanL.K. FriedmanT.C. DoppmanJ.L. CutlerG.B.Jr ChrousosG.P. WilderR.L. GoldP.W. YanovskiJ.A. Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion J Clin Invest. 1996 97 2045 2050 10.1172/JCI1186405072788621793 Search in Google Scholar

[44] Katzke V.A., Kaaks R., Kühn T.: Lifestyle and cancer risk. Cancer J., 2015; 21: 104–110 KatzkeV.A. KaaksR. KühnT. Lifestyle and cancer risk Cancer J. 2015 21 104 110 10.1097/PPO.000000000000010125815850 Search in Google Scholar

[45] Keytruda – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (25.09.2020) Keytruda – Summary of Product Characteristics https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[46] Konda B., Nabhan F., Shah M.H.: Endocrine dysfunction following immune checkpoint inhibitor therapy. Curr. Opin. Endocrinol. Diabetes Obes., 2017; 24: 337–347 KondaB. NabhanF. ShahM.H. Endocrine dysfunction following immune checkpoint inhibitor therapy Curr. Opin. Endocrinol. Diabetes Obes. 2017 24 337 347 10.1097/MED.000000000000035728661915 Search in Google Scholar

[47] Lam K.Y., Lo C.Y.: Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital. Clin. Endocrinol., 2002; 56: 95–101 LamK.Y. LoC.Y. Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital Clin. Endocrinol. 2002 56 95 101 10.1046/j.0300-0664.2001.01435.x11849252 Search in Google Scholar

[48] Lee Y.T., Tan Y.J, Oon C.E.: Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol., 2018; 834: 188–196 LeeY.T. TanY.J OonC.E. Molecular targeted therapy: Treating cancer with specificity Eur. J. Pharmacol. 2018 834 188 196 10.1016/j.ejphar.2018.07.03430031797 Search in Google Scholar

[49] Liu M., Guo F.: Recent updates on cancer immunotherapy. Precis Clin. Med., 2018; 1: 65–74 LiuM. GuoF. Recent updates on cancer immunotherapy Precis Clin. Med. 2018 1 65 74 10.1093/pcmedi/pby011633304530687562 Search in Google Scholar

[50] Lupi I., Zhang J., Gutenberg A., Landek-Salgado M., Tzou S.C., Mori S., Caturegli P.: From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis. Endocrinology, 2011; 152: 4190–4198 LupiI. ZhangJ. GutenbergA. Landek-SalgadoM. TzouS.C. MoriS. CaturegliP. From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis Endocrinology 2011 152 4190 4198 10.1210/en.2011-1004319899421862619 Search in Google Scholar

[51] Manohar S., Kompotiatis P., Thongprayoon C., Cheungpasitporn W., Herrmann J., Herrmann S.M.: Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol. Dial. Transplant., 2019; 34: 108–117 ManoharS. KompotiatisP. ThongprayoonC. CheungpasitpornW. HerrmannJ. HerrmannS.M. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis Nephrol. Dial. Transplant. 2019 34 108 117 10.1093/ndt/gfy10529762725 Search in Google Scholar

[52] Marin-Acevedo J.A., Soyano A.E., Dholaria B., Knutson K.L., Lou Y.: Cancer immunotherapy beyond immune checkpoint inhibitors. J. Hematol. Oncol., 2018; 11: 8 Marin-AcevedoJ.A. SoyanoA.E. DholariaB. KnutsonK.L. LouY. Cancer immunotherapy beyond immune checkpoint inhibitors J. Hematol. Oncol. 2018 11 8 10.1186/s13045-017-0552-6576705129329556 Search in Google Scholar

[53] Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H., Davis M., Carroll R.S., Kaiser U.B.: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin. Cancer Res., 2015; 21: 749–755 MinL. HodiF.S. Giobbie-HurderA. OttP.A. LukeJ.J. DonahueH. DavisM. CarrollR.S. KaiserU.B. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study Clin. Cancer Res. 2015 21 749 755 10.1158/1078-0432.CCR-14-2353433469725538262 Search in Google Scholar

[54] Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.L., Endocrine Society: Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011; 96: 1587–1609 MolitchM.E. ClemmonsD.R. MalozowskiS. MerriamG.R. VanceM.L. Endocrine Society Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline J. Clin. Endocrinol. Metab. 2011 96 1587 1609 10.1210/jc.2011-017921602453 Search in Google Scholar

[55] Ni J., Qiu L.J., Zhang M., Wen P.F., Ye X.R., Liang Y., Pan H.F., Ye D.Q.: CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysis. Endocr. Res., 2014; 39: 180–188 NiJ. QiuL.J. ZhangM. WenP.F. YeX.R. LiangY. PanH.F. YeD.Q. CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysis Endocr. Res. 2014 39 180 188 10.3109/07435800.2013.87916724697361 Search in Google Scholar

[56] Oelkers W.: Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N. Engl. J. Med., 1989; 321: 492–496 OelkersW. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism N. Engl. J. Med. 1989 321 492 496 10.1056/NEJM1989082432108022548097 Search in Google Scholar

[57] Opdivo – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (25.09.2020) Opdivo – Summary of Product Characteristics https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[58] Parakh S., King D., Gan H.K., Scott A.M.: Current development of monoclonal antibodies in cancer therapy. Recent Res. Cancer Res., 2020; 214: 1–70 ParakhS. KingD. GanH.K. ScottA.M. Current development of monoclonal antibodies in cancer therapy Recent Res. Cancer Res. 2020 214 1 70 10.1007/978-3-030-23765-3_131473848 Search in Google Scholar

[59] Pardoll D.M.: The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 2012; 12: 252–264 PardollD.M. The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 2012 12 252 264 10.1038/nrc3239485602322437870 Search in Google Scholar

[60] Persani L., Ferretti E., Borgato S., Faglia G., Beck-Peccoz P.: Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J. Clin. Endocrinol. Metab., 2000; 85: 3631–3635 PersaniL. FerrettiE. BorgatoS. FagliaG. Beck-PeccozP. Circulating thyrotropin bioactivity in sporadic central hypothyroidism J. Clin. Endocrinol. Metab. 2000 85 3631 3635 10.1210/jc.85.10.3631 Search in Google Scholar

[61] Peters C., Brown S.: Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep., 2015; 35: e00225 PetersC. BrownS. Antibody-drug conjugates as novel anti-cancer chemotherapeutics Biosci. Rep. 2015 35 e00225 10.1042/BSR20150089461371226182432 Search in Google Scholar

[62] Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556 PiranavanP. LiY. BrownE. KempE.H. TrivediN. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies J. Clin. Endocrinol. Metab. 2019 104 550 556 10.1210/jc.2018-0115130252069 Search in Google Scholar

[63] Puar T.H., Stikkelbroeck N.M., Smans L.C., Zelissen P.M., Hermus A.R.: Adrenal crisis: Still a deadly event in the 21st century. Am. J. Med., 2016; 129: 339.e1–9 PuarT.H. StikkelbroeckN.M. SmansL.C. ZelissenP.M. HermusA.R. Adrenal crisis: Still a deadly event in the 21st century Am. J. Med. 2016 129 339.e1 9 10.1016/j.amjmed.2015.08.02126363354 Search in Google Scholar

[64] Raghavan R., Brady M.L., Sampson J.H.: Delivering therapy to target: Improving the odds for successful drug development. Ther. Deliv., 2016; 7: 457–481 RaghavanR. BradyM.L. SampsonJ.H. Delivering therapy to target: Improving the odds for successful drug development Ther. Deliv. 2016 7 457 481 10.4155/tde-2016-001627403630 Search in Google Scholar

[65] Rakoff-Nahoum S.: Why cancer and inflammation? Yale J. Biol. Med., 2006; 79: 123–130 Rakoff-NahoumS. Why cancer and inflammation? Yale J. Biol. Med. 2006 79 123 130 Search in Google Scholar

[66] Ruggeri R.M., Campennì A., Giuffrida G., Trimboli P., Giovanella L., Trimarchi F., Cannavò S.: Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know). J. Endocrinol. Invest., 2019; 42: 745–756 RuggeriR.M. CampennìA. GiuffridaG. TrimboliP. GiovanellaL. TrimarchiF. CannavòS. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know) J. Endocrinol. Invest. 2019 42 745 756 10.1007/s40618-018-0984-z30471004 Search in Google Scholar

[67] Scott E.S., Long G.V., Guminski A., Clifton-Bligh R.J., Menzies A.M., Tsang V.H.: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur. J. Endocrinol., 2018; 178: 173–180 ScottE.S. LongG.V. GuminskiA. Clifton-BlighR.J. MenziesA.M. TsangV.H. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma Eur. J. Endocrinol. 2018 178 173 180 10.1530/EJE-17-081029187509 Search in Google Scholar

[68] Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Deng Y., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med., 2018; 378: 2288–2301 SocinskiM.A. JotteR.M. CappuzzoF. OrlandiF. StroyakovskiyD. NogamiN. Rodríguez-AbreuD. Moro-SibilotD. ThomasC.A. BarlesiF. FinleyG. KelschC. LeeA. ColemanS. DengY. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC N. Engl. J. Med. 2018 378 2288 2301 10.1056/NEJMoa171694829863955 Search in Google Scholar

[69] Song M., Giovannucci E.: Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol., 2016; 2: 1154–1161 SongM. GiovannucciE. Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States JAMA Oncol. 2016 2 1154 1161 10.1001/jamaoncol.2016.0843501619927196525 Search in Google Scholar

[70] Suzuki M., Kato C., Kato A.: Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studies. J. Toxicol. Pathol., 2015; 28: 133–139 SuzukiM. KatoC. KatoA. Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studies J. Toxicol. Pathol. 2015 28 133 139 10.1293/tox.2015-0031458820726441475 Search in Google Scholar

[71] Tecentriq – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/tecentriq-epar-product-information_en.pdf (25.09.2020) Tecentriq – Summary of Product Characteristics https://www.ema.europa.eu/en//documents/product-information/tecentriq-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[72] Tolcher A.W.: Antibody drug conjugates: Lessons from 20 years of clinical experience. Ann. Oncol., 2016; 27: 2168–2172 TolcherA.W. Antibody drug conjugates: Lessons from 20 years of clinical experience Ann. Oncol. 2016 27 2168 2172 10.1093/annonc/mdw42427733376 Search in Google Scholar

[73] Toporcov T.N., Wünsch Filho V.: Epidemiological science and cancer control. Clinics, 2018; 73: e627s ToporcovT.N. Wünsch FilhoV. Epidemiological science and cancer control Clinics 2018 73 e627s 10.6061/clinics/2018/e627s614285830281702 Search in Google Scholar

[74] Torino F., Corsello S.M., Salvatori R.: Endocrinological side-effects of immune checkpoint inhibitors. Curr. Opin. Oncol., 2016; 28: 278–287 TorinoF. CorselloS.M. SalvatoriR. Endocrinological side-effects of immune checkpoint inhibitors Curr. Opin. Oncol. 2016 28 278 287 10.1097/CCO.000000000000029327136136 Search in Google Scholar

[75] U.S. Cancer Statistics Working Group. 1999–2013 Incidence and mortality web-based report. www.cdc.gov/uscs (25.09.2020) U.S. Cancer Statistics Working Group 1999–2013 Incidence and mortality web-based report www.cdc.gov/uscs (25.09.2020) Search in Google Scholar

[76] Venetsanaki V., Boutis A., Chrisoulidou A., Papakotoulas P.: Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr. Oncol., 2019; 26: e111–e114 VenetsanakiV. BoutisA. ChrisoulidouA. PapakotoulasP. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors Curr. Oncol. 2019 26 e111 e114 10.3747/co.26.4151638064030853817 Search in Google Scholar

[77] Weber J.S., Postow M., Lao C.D., Schadendorf D.: Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist, 2016; 21: 1230–1240 WeberJ.S. PostowM. LaoC.D. SchadendorfD. Management of adverse events following treatment with anti-programmed death-1 agents Oncologist 2016 21 1230 1240 10.1634/theoncologist.2016-0055506153927401894 Search in Google Scholar

[78] Weiner L.M., Surana R., Wang S.: Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 2010; 10: 317–327 WeinerL.M. SuranaR. WangS. Monoclonal antibodies: Versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 2010 10 317 327 10.1038/nri2744350806420414205 Search in Google Scholar

[79] Win M.A., Thein K.Z., Qdaisat A., Yeung S.C.: Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am. J. Emerg. Med., 2017; 35: 1039.e5–1039.e7 WinM.A. TheinK.Z. QdaisatA. YeungS.C. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism Am. J. Emerg. Med. 2017 35 1039.e5 1039.e7 10.1016/j.ajem.2017.02.04828363614 Search in Google Scholar

[80] World Health Organization. Cancer fact sheet. http://www.who.int/mediacentre//factsheets/fs297/en/ (25.09.2020) World Health Organization Cancer fact sheet http://www.who.int/mediacentre//factsheets/fs297/en/ (25.09.2020) Search in Google Scholar

[81] Yamazaki N., Kiyohara Y., Uhara H., Fukushima S., Uchi H., Shibagaki N., Tsutsumida A., Yoshikawa S., Okuyama R., Ito Y., Tokudome T.: Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol., 2015; 76: 997–1004 YamazakiN. KiyoharaY. UharaH. FukushimaS. UchiH. ShibagakiN. TsutsumidaA. YoshikawaS. OkuyamaR. ItoY. TokudomeT. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma Cancer Chemother. Pharmacol. 2015 76 997 1004 10.1007/s00280-015-2873-x461232126410424 Search in Google Scholar

[82] Yervoy-Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf (25.09.2020) Yervoy-Summary of Product Characteristics https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf (25.09.2020) Search in Google Scholar

[83] Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369 ZhaoC. TellaS.H. Del RiveroJ. KommalapatiA. EbenuwaI. GulleyJ. StraussJ. BrownellI. Anti-PD-L1 treatment induced central diabetes insipidus J. Clin. Endocrinol. Metab. 2018 103 365 369 10.1210/jc.2017-01905580082629220526 Search in Google Scholar